Literature DB >> 31386124

Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017.

Christopher M Jones1, Wilson Compton2, Meena Vythilingam3, Brett Giroir3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31386124      PMCID： PMC6686765          DOI： 10.1001/jama.2019.7988

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  18 in total

1.  Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.

Authors:  Bradley D Stein; Christopher M Jones; Rosanna Smart; Flora Sheng; Mark Sorbero
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

Review 2.  Claims-based measures of prescription opioid utilization: A practical guide for researchers.

Authors:  Sara E Heins; Christine Buttorff; Courtney Armstrong; Rosalie Liccardo Pacula
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

3.  Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.

Authors:  Robin A Pollini; Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2022-03-19

4.  Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014-2018.

Authors:  Traci C Green; Corey Davis; Ziming Xuan; Alexander Y Walley; Jeffrey Bratberg
Journal:  Am J Public Health       Date:  2020-04-16       Impact factor: 9.308

5.  Opioid Use Disorder and Overdose in Older Adults With Breast, Colorectal, or Prostate Cancer.

Authors:  Andrew W Roberts; Samantha Eiffert; Elizabeth M Wulff-Burchfield; Stacie B Dusetzina; Devon K Check
Journal:  J Natl Cancer Inst       Date:  2021-04-06       Impact factor: 13.506

6.  Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.

Authors:  Robin A Pollini; Rebecca Joyce; Jenny E Ozga-Hess; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-08

7.  Naloxone Prescribing Among Frequent Opioid Prescribers in Medicare Part D from 2013 to 2017: a Retrospective Study.

Authors:  Andrew W Roberts
Journal:  J Gen Intern Med       Date:  2020-05-06       Impact factor: 5.128

8.  Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy.

Authors:  Simeon D Kimmel; Alexander Y Walley; Sara Lodi; Leah S Forman; Jane M Liebschutz; Marlene C Lira; Theresa W Kim; Carlos Del Rio; Jeffrey H Samet; Judith I Tsui
Journal:  AIDS       Date:  2021-03-15       Impact factor: 4.632

9.  Concurrent Naloxone Dispensing Among Individuals with High-Risk Opioid Prescriptions, USA, 2015-2019.

Authors:  Gery P Guy; Andrea E Strahan; Tamara Haegerich; Jan L Losby; Kathleen Ragan; Mary E Evans; Christopher M Jones
Journal:  J Gen Intern Med       Date:  2021-03-09       Impact factor: 6.473

10.  Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone" [Response To Letter].

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.